Related Experiment Videos
Immunomodulation of atherosclerosis: implications for vaccine development
Jan Nilsson1, Göran K Hansson, Prediman K Shah
1Department of Medicine, Malmö University Hospital, Lund University, Sweden. Jan.Nilsson@medforsk.mas.lu.se
Arteriosclerosis, Thrombosis, and Vascular Biology
|October 30, 2004
Summary
This review explores how modulating immune responses, by suppressing harmful or activating beneficial ones, offers new strategies for preventing and treating atherosclerosis. Identifying specific antigens and adjuvants is key to this immunomodulatory approach.
Area of Science:
- Immunology
- Cardiovascular Medicine
- Pathophysiology
Background:
- Immune system activation is observed across atherosclerosis stages.
- Immune responses can both promote (arterial inflammation) and inhibit atherosclerosis.
- This duality suggests targeted immunomodulation as a therapeutic strategy.
Purpose of the Study:
- To review experimental studies on immunomodulatory approaches for atherosclerosis treatment.
- To explore the potential of selective suppression of proatherogenic and activation of antiatherogenic immune responses.
Main Methods:
- Identification of antigens that influence atherosclerosis development.
- Modulation of immune responses through antigen presentation with adjuvants.
- Investigation of different routes of administration for immunomodulatory agents.
Main Results:
- Experimental studies demonstrate the feasibility of using immunomodulation in atherosclerosis.
- Specific immune responses can be targeted to either promote or inhibit disease progression.
- Antigen-adjuvant combinations and administration routes significantly impact immune modulation.
Conclusions:
- Targeted immunomodulation presents a promising avenue for atherosclerosis prevention and treatment.
- Further research into specific antigens, adjuvants, and delivery methods is warranted.
- Selective manipulation of immune responses holds potential for managing arterial inflammation.